mouse monoclonal IgG2b; Skp1 p19 Antibody (H-6) is an IgG2b κ mouse monoclonal Skp1 p19 antibody (also designated S-Phase Kinase Associated Protein 1 antibody, OCP-II antibody, TCEB1L antibody, EMC19 antibody, OCP2 antibody, P19A antibody, Transcription Elongation Factor B Polypeptide 1-Like antibody, Cyclin-A/CDK2-Associated Protein P19 antibody, S-Phase Kinase-Associated Protein 1 antibody, Organ Of Corti Protein II antibody, Organ Of Corti Protein 2 antibody, P19skp1 antibody, SKP1A antibody, OCP-2 antibody, SIII antibody, or RNA Polymerase II Elongation Factor-Like Protein OCP2 antibody) that detects the Skp1 p19 protein of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA. Skp1 p19 Antibody (H-6) is available as both the non-conjugated anti-Skp1 p19 antibody form, as well as multiple conjugated forms of anti-Skp1 p19 antibody, including agarose, PE, FITC and multiple Alexa Fluor® conjugates. The critical role that the family of regulatory proteins known as cyclins plays in eukaryotic cell cycle regulation is well established. The best characterized cyclin complex is the mitotic cyclin B/Cdc2 p34 kinase, the active component of MPF (maturation promoting factor). Cyclin A accumulates prior to cyclin B in the cell cycle, appears to be involved in control of S phase and has been shown to associate with cyclin dependent kinase-2 (Cdk2). In addition, cyclin A has been implicated in cell transformation and is found in complexes with E1A, transcription factors DP-1 and E2F and retino-blastoma protein p110. Two cyclin A-Cdk2 complex binding proteins, Skp1 p19 and Skp2 p45, have been described. Although the Skps (S phase kinase-associated proteins) associate with the active cyclin A-Cdk2 complex, they do not exhibit any regulatory effects on the complex. Abolition of Skp2 p45 function by either microinjection of anti-p45 antibodies or addition of antisense oligonucleotides prevents entry into S phase of both normal and transformed cells.